Merus Announces Promising Phase 2 Trial Results

Merus ( (MRUS) ) has shared an announcement.

On May 22, 2025, Merus announced interim clinical data from a phase 2 trial of its bispecific antibody, petosemtamab, in combination with pembrolizumab. The trial showed promising results with a 63% overall response rate among 43 evaluable patients, including complete and partial responses across various cancer types and PD-L1 levels. The treatment was generally well tolerated, with no significant overlapping toxicities observed. The company plans to potentially share top line interim results of phase 3 trials in 2026.

The most recent analyst rating on (MRUS) stock is a Buy with a $67.00 price target. To see the full list of analyst forecasts on Merus stock, see the MRUS Stock Forecast page.

Spark’s Take on MRUS Stock

According to Spark, TipRanks’ AI Analyst, MRUS is a Neutral.

Merus’s mixed financial performance, characterized by growth but ongoing profitability and cash flow issues, significantly impacts the score. Positive technical indicators provide a more favorable outlook, offsetting some financial concerns, but the valuation remains a challenge due to negative earnings.

To see Spark’s full report on MRUS stock, click here.

More about Merus

Merus N.V. operates in the biotechnology industry, focusing on the development of innovative bispecific antibody therapeutics for the treatment of cancer.

Average Trading Volume: 995,997

Technical Sentiment Signal: Strong Buy

Current Market Cap: $3.52B

See more data about MRUS stock on TipRanks’ Stock Analysis page.